84 related articles for article (PubMed ID: 32507911)
1. Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience.
Bekoz H; Ozbalak M; Karadurmus N; Paydas S; Turker A; Toptas T; Tuglular TF; Altuntas F; Cakar MK; Sonmez M; Gulbas Z; Demir N; Kaynar L; Yildirim R; Karadogan I; Arat M; Kapucu I; Aslan NA; Ozkocaman V; Turgut M; Yuksel MK; Ozcan M; Hacioglu SK; Barista I; Demirkaya M; Saydam G; Toprak SK; Yilmaz M; Demirkol O; Ferhanoglu B
Ann Hematol; 2020 Nov; 99(11):2565-2576. PubMed ID: 32507911
[TBL] [Abstract][Full Text] [Related]
2. Post-marketing surveillance of the safety and effectiveness of nivolumab for classic Hodgkin lymphoma in Japan.
Kawasaki A; Hatake K; Matsumura I; Izutsu K; Hoshino T; Akamatsu A; Kakuuchi A; Tobinai K
Int J Hematol; 2024 Jun; 119(6):667-676. PubMed ID: 38521840
[TBL] [Abstract][Full Text] [Related]
3. Real-World Multicenter Study of PD-1 Blockade in HIV-Associated Classical Hodgkin Lymphoma Across the United States.
Lurain K; Zarif TE; Ramaswami R; Nassar AH; Adib E; Abdel-Wahab N; Chintapally N; Drolen CE; Feldman T; Haykal T; Nebhan CA; Kambhampati S; Li M; Mittra A; Lorentsen M; Kim C; Drakaki A; Morse M; Johnson DB; Mangla A; Dittus C; Ravi P; Baiocchi RA; Chiao EY; Rubinstein PG; Yellapragada SV; LaCasce AS; Sonpavde GP; Naqash AR; Herrera AF
Clin Lymphoma Myeloma Leuk; 2024 Apr; ():. PubMed ID: 38714474
[TBL] [Abstract][Full Text] [Related]
4. Italian real life experience with ibrutinib: results of a large observational study on 77 relapsed/refractory mantle cell lymphoma.
Broccoli A; Casadei B; Morigi A; Sottotetti F; Gotti M; Spina M; Volpetti S; Ferrero S; Spina F; Pisani F; Merli M; Visco C; Paolini R; Zilioli VR; Baldini L; Di Renzo N; Tosi P; Cascavilla N; Molica S; Ilariucci F; Rigolin GM; D'Alò F; Vanazzi A; Santambrogio E; Marasca R; Mastrullo L; Castellino C; Desabbata G; Scortechini I; Trentin L; Morello L; Argnani L; Zinzani PL
Oncotarget; 2018 May; 9(34):23443-23450. PubMed ID: 29805746
[TBL] [Abstract][Full Text] [Related]
5. Brentuximab vedotin plus nivolumab as first-line therapy in older or chemotherapy-ineligible patients with Hodgkin lymphoma (ACCRU): a multicentre, single-arm, phase 2 trial.
Cheson BD; Bartlett NL; LaPlant B; Lee HJ; Advani RJ; Christian B; Diefenbach CS; Feldman TA; Ansell SM
Lancet Haematol; 2020 Nov; 7(11):e808-e815. PubMed ID: 33010817
[TBL] [Abstract][Full Text] [Related]
6. Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial.
Diefenbach CS; Hong F; Ambinder RF; Cohen JB; Robertson MJ; David KA; Advani RH; Fenske TS; Barta SK; Palmisiano ND; Svoboda J; Morgan DS; Karmali R; Sharon E; Streicher H; Kahl BS; Ansell SM
Lancet Haematol; 2020 Sep; 7(9):e660-e670. PubMed ID: 32853585
[TBL] [Abstract][Full Text] [Related]
7. Final results of a phase II study of nivolumab in Japanese patients with relapsed or refractory classical Hodgkin lymphoma.
Maruyama D; Terui Y; Yamamoto K; Fukuhara N; Choi I; Kuroda J; Ando K; Hattori A; Tobinai K
Jpn J Clin Oncol; 2020 Oct; 50(11):1265-1273. PubMed ID: 32776097
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic Updates for Relapsed and Refractory Classical Hodgkin Lymphoma.
Voorhees TJ; Beaven AW
Cancers (Basel); 2020 Oct; 12(10):. PubMed ID: 33050054
[TBL] [Abstract][Full Text] [Related]
9. A peripheral immune signature of responsiveness to PD-1 blockade in patients with classical Hodgkin lymphoma.
Cader FZ; Hu X; Goh WL; Wienand K; Ouyang J; Mandato E; Redd R; Lawton LN; Chen PH; Weirather JL; Schackmann RCJ; Li B; Ma W; Armand P; Rodig SJ; Neuberg D; Liu XS; Shipp MA
Nat Med; 2020 Sep; 26(9):1468-1479. PubMed ID: 32778827
[TBL] [Abstract][Full Text] [Related]
10. A Study of Safety and Efficacy of Nivolumab and Bendamustine (NB) in Patients With Relapsed/Refractory Hodgkin Lymphoma After Nivolumab Monotherapy Failure.
Lepik KV; Mikhailova NB; Kondakova EV; Zalyalov YR; Fedorova LV; Tsvetkova LA; Kotselyabina PV; Borzenkova ES; Babenko EV; Popova MO; Darskaya EI; Baykov VV; Moiseev IS; Afanasyev BV
Hemasphere; 2020 Jun; 4(3):e401. PubMed ID: 32647803
[TBL] [Abstract][Full Text] [Related]
11. C(h)AR-ting a new course in incurable lymphomas: CAR T cells for mantle cell and follicular lymphomas.
Jacobson CA; Maus MV
Blood Adv; 2020 Nov; 4(22):5858-5862. PubMed ID: 33232481
[TBL] [Abstract][Full Text] [Related]
12. Multidisciplinary Clinical Approach to Cancer Patients with Immune-Related Adverse Events Induced by Checkpoint Inhibitors.
Londoño MC; Reig M;
Cancers (Basel); 2020 Nov; 12(11):. PubMed ID: 33228219
[TBL] [Abstract][Full Text] [Related]
13. Programmed Cell Death-One Inhibition Therapy in Classical Hodgkin Lymphoma.
Al-Hadidi SA; Chuang HH; Miranda RN; Lee HJ
Clin Lymphoma Myeloma Leuk; 2021 Feb; 21(2):e105-e111. PubMed ID: 33160934
[TBL] [Abstract][Full Text] [Related]
14. Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study.
Kuruvilla J; Ramchandren R; Santoro A; Paszkiewicz-Kozik E; Gasiorowski R; Johnson NA; Fogliatto LM; Goncalves I; de Oliveira JSR; Buccheri V; Perini GF; Goldschmidt N; Kriachok I; Dickinson M; Komarnicki M; McDonald A; Ozcan M; Sekiguchi N; Zhu Y; Nahar A; Marinello P; Zinzani PL;
Lancet Oncol; 2021 Apr; 22(4):512-524. PubMed ID: 33721562
[TBL] [Abstract][Full Text] [Related]
15. Demographical and Clinical Features of Marginal Zone Lymphomas: A Retrospective Study of Turkish Oncology Group (TOG).
Türkkan G; Alkan A; Paydaş S; Tanrıverdi Ö; Karakaş Y; Karadurmuş N; Sakin A; Temiz S; Arpacı E; Akın M; Menekşe S; Şen CA; Barışta İ
Indian J Hematol Blood Transfus; 2020 Oct; 36(4):640-645. PubMed ID: 33100705
[TBL] [Abstract][Full Text] [Related]
16. A Phase 2 Study of Nivolumab Using a Fixed Dose of 40 mg (Nivo40) in Patients With Relapsed/Refractory Hodgkin Lymphoma.
Lepik KV; Fedorova LV; Kondakova EV; Zalyalov YR; Babenko EV; Lepik EE; Kotselyabina PV; Beynarovich AV; Popova MO; Volkov NP; Stelmakh LV; Baykov VV; Moiseev IS; Mikhailova NB; Kulagin AD; Afanasyev BV
Hemasphere; 2020 Oct; 4(5):e480. PubMed ID: 33062947
[TBL] [Abstract][Full Text] [Related]
17. Pembrolizumab for the treatment of Hodgkin Lymphoma.
Al Hadidi SA; Lee HJ
Expert Opin Biol Ther; 2020 Nov; 20(11):1275-1282. PubMed ID: 33006479
[TBL] [Abstract][Full Text] [Related]
18. Emerging Therapies in Relapsed and Refractory Hodgkin Lymphoma: What Comes Next After Brentuximab Vedotin and PD-1 Inhibition?
Othman T; Herrera A; Mei M
Curr Hematol Malig Rep; 2021 Feb; 16(1):1-7. PubMed ID: 33409966
[TBL] [Abstract][Full Text] [Related]
19. Real-World Healthcare Resource Utilization in Patients with Classical Hodgkin Lymphoma Treated with Pembrolizumab and Nivolumab in the USA.
Laliberté F; Raut M; Yang X; Germain G; Nahar A; Desai KD; MacKnight SD; Sen SS; Duh MS
Target Oncol; 2021 Jan; 16(1):85-94. PubMed ID: 33284424
[TBL] [Abstract][Full Text] [Related]
20. KEYNOTE-013 4-year follow-up of pembrolizumab in classical Hodgkin lymphoma after brentuximab vedotin failure.
Armand P; Kuruvilla J; Michot JM; Ribrag V; Zinzani PL; Zhu Y; Marinello P; Nahar A; Moskowitz CH
Blood Adv; 2020 Jun; 4(12):2617-2622. PubMed ID: 32556281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
